Document Detail


Hyperhomocysteinemia decreases bone blood flow.
MedLine Citation:
PMID:  21339911     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Elevated plasma levels of homocysteine (Hcy), known as hyperhomocysteinemia (HHcy), are associated with osteoporosis. A decrease in bone blood flow is a potential cause of compromised bone mechanical properties. Therefore, we hypothesized that HHcy decreases bone blood flow and biomechanical properties. To test this hypothesis, male Sprague-Dawley rats were treated with Hcy (0.67 g/L) in drinking water for 8 weeks. Age-matched rats served as controls. At the end of the treatment period, the rats were anesthetized. Blood samples were collected from experimental or control rats. Biochemical turnover markers (body weight, Hcy, vitamin B(12), and folate) were measured. Systolic blood pressure was measured from the right carotid artery. Tibia blood flow was measured by laser Doppler flow probe. The results indicated that Hcy levels were significantly higher in the Hcy-treated group than in control rats, whereas vitamin B(12) levels were lower in the Hcy-treated group compared with control rats. There was no significant difference in folate concentration and blood pressure in Hcy-treated versus control rats. The tibial blood flow index of the control group was significantly higher (0.78 ± 0.09 flow unit) compared with the Hcy-treated group (0.51 ± 0.09). The tibial mass was 1.1 ± 0.1 g in the control group and 0.9 ± 0.1 in the Hcy-treated group. The tibia bone density was unchanged in Hcy-treated rats. These results suggest that Hcy causes a reduction in bone blood flow, which contributes to compromised bone biomechanical properties.
Authors:
Neetu Tyagi; Thomas P Vacek; John T Fleming; Jonathan C Vacek; Suresh C Tyagi
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2011-01-25
Journal Detail:
Title:  Vascular health and risk management     Volume:  7     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2011  
Date Detail:
Created Date:  2011-02-22     Completed Date:  2011-06-13     Revised Date:  2011-07-25    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  31-5     Citation Subset:  IM    
Affiliation:
Department of Physiology and Biophysics, School of Medicine, University of Louisville, KY, USA. n0tyag01@louisville.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Biological Markers / blood
Biomechanics
Blood Pressure
Bone Density
Bone Remodeling
Disease Models, Animal
Folic Acid / blood
Homocysteine / blood*
Hyperhomocysteinemia / blood,  complications*,  physiopathology
Laser-Doppler Flowmetry
Male
Osteoporosis / blood,  etiology*,  physiopathology
Rats
Rats, Sprague-Dawley
Regional Blood Flow
Tibia / blood supply*,  physiopathology
Time Factors
Up-Regulation
Vitamin B 12 / blood
Grant Support
ID/Acronym/Agency:
HL-71010/HL/NHLBI NIH HHS; NS-51568/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 454-28-4/Homocysteine; 59-30-3/Folic Acid; 68-19-9/Vitamin B 12
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antiplatelet combinations for prevention of atherothrombotic events.
Next Document:  Congenital agenesis of internal carotid artery with ipsilateral Horner presenting as focal neurologi...